REGENXBIO Files 8-K: Other Events & Exhibits
Ticker: RGNX · Form: 8-K · Filed: Mar 11, 2024 · CIK: 1590877
Sentiment: neutral
Topics: filing, sec, regulatory
Related Tickers: RGNX
TL;DR
REGENXBIO filed an 8-K on March 11th for events on March 6th - details pending.
AI Summary
REGENXBIO Inc. filed an 8-K on March 11, 2024, reporting an event that occurred on March 6, 2024. The filing pertains to 'Other Events' and 'Financial Statements and Exhibits' but does not disclose specific details about the nature of these events or any associated financial figures within the provided text.
Why It Matters
This 8-K filing indicates that REGENXBIO Inc. has reported significant events and submitted financial exhibits to the SEC, which could contain material updates for investors.
Risk Assessment
Risk Level: medium — The filing is an 8-K, which typically reports material events, but the provided text lacks specific details, creating uncertainty about the nature and impact of these events.
Key Players & Entities
- REGENXBIO Inc. (company) — Registrant
- March 6, 2024 (date) — Earliest event reported
- March 11, 2024 (date) — Date of report
- 001-37553 (other) — SEC File Number
- 47-1851754 (other) — IRS Employer Identification No.
FAQ
What specific 'Other Events' are being reported by REGENXBIO Inc. in this 8-K filing?
The provided text of the 8-K filing does not specify the details of the 'Other Events'.
What are the 'Financial Statements and Exhibits' that REGENXBIO Inc. is filing?
The filing indicates that 'Financial Statements and Exhibits' are being submitted, but the specific content is not detailed in the provided text.
When was the earliest event reported in this 8-K filing?
The earliest event reported in this 8-K filing occurred on March 6, 2024.
What is REGENXBIO Inc.'s principal executive office address?
REGENXBIO Inc.'s principal executive office is located at 9804 Medical Center Drive, Rockville, Maryland 20850.
What is the SEC file number for REGENXBIO Inc.?
REGENXBIO Inc.'s SEC file number is 001-37553.
Filing Stats: 1,135 words · 5 min read · ~4 pages · Grade level 10.6 · Accepted 2024-03-11 08:00:31
Key Financial Figures
- $0.0001 — ich registered Common Stock, par value $0.0001 per share RGNX The Nasdaq Global Se
- $23.00 — on Stock"), at a price to the public of $23.00 per share, and 1,521,740 pre-funded war
- $22.9999 — rrants, the "Securities") at a price of $22.9999 per Pre-funded Warrant, which represent
- $131.2 m — fering are expected to be approximately $131.2 million, after deducting underwriting dis
- $150.9 million — ons and estimated offering expenses, or $150.9 million if the Underwriters exercise in full th
Filing Documents
- d795828d8k.htm (8-K) — 31KB
- d795828dex11.htm (EX-1.1) — 172KB
- d795828dex41.htm (EX-4.1) — 68KB
- d795828dex51.htm (EX-5.1) — 16KB
- d795828dex991.htm (EX-99.1) — 11KB
- g795828g0308073114437.jpg (GRAPHIC) — 3KB
- g795828g0308101526031.jpg (GRAPHIC) — 1KB
- g795828g44d35.jpg (GRAPHIC) — 13KB
- 0001193125-24-064353.txt ( ) — 515KB
- rgnx-20240306.xsd (EX-101.SCH) — 3KB
- rgnx-20240306_lab.xml (EX-101.LAB) — 17KB
- rgnx-20240306_pre.xml (EX-101.PRE) — 11KB
- d795828d8k_htm.xml (XML) — 3KB
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 1.1 Underwriting Agreement, dated March 6, 2024, among REGENXBIO Inc. and Morgan Stanley & Co. LLC, Goldman Sachs & Co. LLC, Barclays Capital Inc. and Stifel, Nicolaus & Company, Incorporated, as representatives of the Underwriters. 4.1 Form of Pre-funded Warrant. 5.1 Opinion of Covington & Burling LLP. 23.1 Consent of Covington & Burling LLP (included as part of Exhibit 5.1). 99.1 Press release dated March 6, 2024. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document).
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. REGENXBIO INC. Date: March 11, 2024 By: /s/ Patrick J. Christmas II Patrick J. Christmas II Executive Vice President, Chief Legal Officer